Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
Magnus TobiassonTatjana PandzicJohanna IllmanLars NilssonSimone WeströmElisabeth EjerbladGitte OlesenAndreas BjörklundAstrid Olsnes KittangOlle WerleniusFryderyk LorentzBengt RasmussenJörg CammengaDuruta WeberCarolin LindholmJoel WigghMarios DimitriouAnn Elin MoenLaimei Yip LundströmLena von BahrKarin Baltzer-SollanderMartin JäderstenSoili KytöläGunilla WalldinQamar-Un-Nisa ChaudhryKirsten GroenbaekStephan MielkeSten Eirik W JacobsenFreja EbelingLucia CavelierLone Smidstrup FriisIngunn DybedalEva Hellström LindbergPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Assessment of individualized MRD using NGS + ddPCR is feasible and can be used for early detection of relapse. Positive MRD is associated with shorter RFS and OS (ClinicalTrials.gov identifier: NCT02872662).
Keyphrases